Investors Urged to Lead PepGen Securities Fraud Class Action Lawsuit

In a recent announcement, the Rosen Law Firm, a respected global advocate for investor rights, is urging individuals who purchased securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024, and March 3, 2025, to take action. This call to action comes ahead of a crucial deadline on August 8, 2025, regarding participation in a class action lawsuit.

Why This Matters

For investors who acquired PepGen securities during the specified class period, there is potential for compensation without the burden of out-of-pocket costs, thanks to a contingency fee arrangement. This means that if you are eligible, there are no upfront fees, and payment is contingent upon a successful outcome.

How to Join the Class Action

If you believe you qualify to be part of this legal action, you can easily join the class action by visiting Rosen Law Firm's submission page. Alternatively, for personalized assistance, you can contact Phillip Kim, Esq. directly at 866-767-3653 or via email at [email protected]. It is essential to note that a class action lawsuit is already in progress, and those intending to serve as lead plaintiffs must file their motion no later than the aforementioned deadline. A lead plaintiff acts as a representative for all class members and steers the litigation process.

The Case Details

The lawsuit alleges that throughout the class period, the defendants involved made numerous false and misleading statements and failed to disclose critical information regarding PepGen's key product, PGN-ED051. Specifically, the lawsuit claims the defendants misrepresented the drug's effectiveness and safety, and failed to disclose deficiencies in the CONNECT2 study essential for obtaining U.S. Food and Drug Administration (FDA) approval. As a result of these misleading communications, PepGen’s clinical, regulatory, and commercial prospects appeared much brighter than they truly were.

When the truthful details finally emerged in the market, investors incurred significant losses, leading to the filing of this class action lawsuit.

The Importance of Qualified Counsel

Rosen Law Firm emphasizes the need for investors to select qualified legal representation with proven success in handling leadership roles in class action lawsuits. Many firms sending out notifications may lack the necessary experience and resources to successfully litigate such cases. Firms that typically act as intermediaries may merely refer clients to other law firms without adequate experience in actually engaging in litigations.

Why Choose Rosen Law Firm?

The Rosen Law Firm is dedicated to representing investors globally, with immense focus on securities class actions and shareholder derivative litigation. The firm boasts a remarkable track record, having achieved the largest settlement in history against a Chinese company at the time and ranking first in the number of securities class action settlements in 2017. They have recovered hundreds of millions for investors, including over $438 million in 2019 alone. The founding partner, Laurence Rosen, earned recognition as a Titan of the Plaintiffs' Bar in 2020 by Law360. Many attorneys within the firm have garnered accolades from Lawdragon and Super Lawyers for their expertise.

Stay Informed

For continuous updates on the legal proceedings and further information, investors are encouraged to follow the Rosen Law Firm on social media platforms such as LinkedIn, Twitter, or Facebook.

Disclaimer: Prior results do not guarantee a similar outcome. No class has been certified yet. Until that point, potential class members are not represented unless they have retained their own counsel. Investors have the option to remain absent class members and may choose to take no actions currently. Their eligibility for any potential future recovery does not depend on taking any action to serve as a lead plaintiff.

For more information, contact the Rosen Law Firm at their New York office, located at 275 Madison Avenue, 40th Floor, New York, NY 10016. You can reach them at telephone number (212) 686-1060 or toll-free at (866) 767-3653.